(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Greece eyes migrant repatriation centres outside the EU - 2Ukraine confirms defence and energy ministers at second attempt
- 3Daily Briefing: A bad flu season gets worse
- 4Chicago reports first rabies-positive dog in 61 years. What we know.
- 5The 1st full moon of 2026 rises tonight! Here's what to expect from January's supermoon Wolf Moon
- 6 Arranging Administrations to Change Your Open air Space
- Tens of thousands protest as far-right AfD forms new youth group
- 10 Famous Frozen yogurt Flavors All over The Planet
- Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- The most effective method to Oversee Unsold SUVs in the Car Business
- 10 Moving Design Frill for Summer 2023
- RFK Jr.'s vaccine panel delays hepatitis B shot vote after chaotic meeting
- Flu activity rises sharply across US with 7.5 million cases, CDC data shows
